Jose Karam

20PUBLICATIONS

114CO-AUTHORS

Toxicology (incl. clinical toxicology)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersCatalysis and mechanisms of reactions

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (20)

Sort by Publication Date:

|Jun 20, 2026

5x-Multiplier Versus 3-Tier Model: A Pragmatic Randomized Clinical Trial for Discharge Opioid Prescriptions After Intra-Abdominal Cancer Surgery.

|Aug 25, 2025

High-Dose Chemotherapy for Multiply or Poor-Risk Relapsed Germ Cell Tumors.

Yago Nieto, John F Ward, Wayne Hofstetter

|Jul 02, 2025

Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase-Deficient Renal Cell Carcinoma.

Niki M Zacharias, Manuel Ozambela, Menuka Karki

|Jun 30, 2025

5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Randomized Clinical Trial Protocol.

Brittany C Fields, Timothy E Newhook, Heather A Lillemoe

|Feb 21, 2025

Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial.

Sangeeta Goswami, Jianjun Gao, Sreyashi Basu

|Jan 09, 2025

Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma.

Tejas Jammihal, Renee Maria Saliby, Chris Labaki

Pageof 4

Frequent Collaborators

Matthew T Campbell

Surena F Matin

Christopher G Wood

Sreyashi Basu

Alexsandra B Espejo

Padmanee Sharma

Amishi Y Shah

Pavlos Msaouel

Jianjun Gao

Rebecca Slack Tidwell

Frequent Collaborators

Matthew T Campbell

Surena F Matin

Christopher G Wood

Sreyashi Basu